Omitting Cortical Renorrhaphy in Robot-Assisted Partial Nephrectomy: Is it Safe? A Single Center Large Case Series

2020 ◽  
Vol 34 (8) ◽  
pp. 840-846
Author(s):  
Ibraheem Alrishan Alzouebi ◽  
Aled Williams ◽  
Nambi Rajan Thiagarjan ◽  
Manal Kumar
Keyword(s):  
Partial Nephrectomy ◽  
Case Series ◽  
Single Center ◽  
Robot Assisted ◽  
Large Case Series ◽  
Large Case

Melanoma Involving the Gastrointestinal (GI) Tract: Single Center Large Case Series

2017 ◽  
Vol 152 (5) ◽  
pp. S883-S884
Author(s):  
Danielle La Selva ◽  
Richard A. Kozarek ◽  
Russell Dorer ◽  
Michael Gluck
Keyword(s):  
Case Series ◽  
Single Center ◽  
Gi Tract ◽  
Large Case Series ◽  
Large Case

scholarly journals EUS-guided hepaticoenterostomy with using a dedicated plastic stent for the benign pancreaticobiliary diseases: A single-center study of a large case series

2021 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Takao Itoi ◽  
Yukitoshi Matsunami ◽  
Atsushi Sofuni ◽  
Takayoshi Tsuchiya ◽  
Kentaro Ishii ◽  
...  
Keyword(s):  
Case Series ◽  
Single Center ◽  
Plastic Stent ◽  
Single Center Study ◽  
Large Case Series ◽  
Large Case ◽  
Center Study

Tips and tricks in endoscopic papillectomy of ampullary tumors: single-center experience with large case series (with videos)

2015 ◽  
Vol 22 (6) ◽  
pp. E22-E27 ◽  
Author(s):  
Shujiro Tsuji ◽  
Takao Itoi ◽  
Atsushi Sofuni ◽  
Shuntaro Mukai ◽  
Ryosuke Tonozuka ◽  
...  
Keyword(s):  
Case Series ◽  
Tips And Tricks ◽  
Single Center ◽  
Single Center Experience ◽  
Endoscopic Papillectomy ◽  
Large Case Series ◽  
Ampullary Tumors ◽  
Large Case

Surgery-Related Outcomes and Postoperative Split Renal Function by Scintigraphy Evaluation in Robot-Assisted Partial Nephrectomy in Complex Renal Tumors: An Initial Case Series

2015 ◽  
Vol 29 (1) ◽  
pp. 29-34 ◽  
Author(s):  
Kazushi Tanaka ◽  
Junya Furukawa ◽  
Katsumi Shigemura ◽  
Nobuyuki Hinata ◽  
Takeshi Ishimura ◽  
...  
Keyword(s):  
Renal Function ◽  
Partial Nephrectomy ◽  
Case Series ◽  
Renal Tumors ◽  
Robot Assisted ◽  
Split Renal Function

Myelopathy Due to CAR-T Related Neurotoxicity Treated with Siltuximab

2021 ◽  
pp. 10.1212/CPJ.0000000000001078
Author(s):  
Yasmin Aghajan ◽  
Alison Yu ◽  
Caron A. Jacobson ◽  
Austin I. Kim ◽  
Leslie Kean ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Hematologic Malignancy ◽  
Case Series ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Car T ◽  
Large Case Series ◽  
Large Case

Chimeric antigen receptor T (CART) cell therapy is highly effective for relapsed/refractory hematologic malignancy [1,2]; however, cytokine release syndrome (CRS) and neurotoxicity are observed in up to 77% of patients [3]. In large case series, the most common presentations of neurotoxicity were encephalopathy (57%), headache (42%), tremor (38%) and aphasia (35%). CART mediated spinal cord toxicity is not well characterized. Structural neurologic damage (stroke and intracranial hemorrhage) was only observed in 1-2% and seizures were seen in 1%-8% of cases [3, 4]. Neuroimaging findings in patients with neurotoxicity are rare and not specific.

scholarly journals Donor Screening for Fecal Microbiota Transplantation

2020 ◽  
Vol 95 (3) ◽  
pp. 181-187
Author(s):  
Han Hee Lee ◽  
Young-Seok Cho
Keyword(s):  
Randomized Clinical Trials ◽  
Fecal Microbiota Transplantation ◽  
Case Series ◽  
Fecal Microbiota ◽  
Resistant Bacteria ◽  
Screening Process ◽  
Antibiotic Resistant ◽  
Donor Screening ◽  
Large Case Series ◽  
Large Case

Fecal microbiota transplantation (FMT), which has been established as the standard treatment for recurrent <i>Clostroides</i> difficile infection, may also play a role in the management of other diseases associated with dysbiosis of the gut microbiota. To ensure efficacy and safety of FMT, an appropriate donor screening process is required. The main purpose of donor screening is to check for infectious diseases that could be transmitted to the recipient. The screening process involves a medical history questionnaire, and blood and stool testing. Several randomized clinical trials and large case series on FMT reported no, or few, adverse events related to infection by following this donor screening process. However, there is still concern over the transmission of antibiotic-resistant bacteria. In addition, a low donor acceptance rate due to rigorous screening makes donor recruitment difficult, and also imposes a significant cost burden. A consensus on the most crucial elements of donor screening is needed for wide application of FMT.

Sign in / Sign up

Export Citation Format

Share Document